Pfizer Announces European Union Approval of a New Form of Lipitor (atorvastatin) for Use in Children

By Pfizer Inc., PRNE
Monday, July 5, 2010

EU Regulation Allows Pfizer to Apply to Extend Lipitor Patent Protection by Six Months in Certain EU Countries

NEW YORK, July 6, 2010 - Pfizer Inc. (NYSE: PFE) announced it has received European Commission
approval of a new chewable form of Lipitor (atorvastatin calcium) suitable
for use in children aged 10 or older with high levels of LDL ("bad")
cholesterol and high triglycerides due to the inherited disorder familial
hypercholesterolemia and other primary causes, which can increase the risk of
heart disease and premature death. This pediatric indication has also been
approved for the currently available tablet form of Lipitor.



The Decision to approve the use of atorvastatin in these pediatric
patients in Europe is based on the results of a pediatric investigation plan
(PIP) filed by Pfizer with the European Medicines Agency (EMA) in November
. Investigations into pediatric use are required by recent European
pediatric regulations(1) in an effort to encourage pharmaceutical companies
to increase understanding of the use of medicines in children. Pfizer hopes
to improve treatment options for such pediatric patients, reflecting its
ongoing support for patients at risk of cardiovascular disease.

To support the investments necessary to conduct clinical trials in
children, the EU created certain incentives, including the availability of a
six-month extension to an existing patent extension, also known as a
supplementary protection certificate (SPC). As previously announced in
November 2009, Pfizer intends to apply for the additional six months of
patent protection in European countries where it has an SPC. A
country-by-country process will be required to secure this patent term

Based on the results of Pfizer-sponsored trials, in March, the EMA's
Committee for Medicinal Products for Human Use (CHMP) recommended that a
pediatric-appropriate formulation of Lipitor (chewable tablets) be approved
for the treatment of hypercholesterolaemia in adolescents and children aged
10 years or older, and the approval of this indication for the currently
available presentations of Lipitor (film-coated tablets). The European
Commission Decision formalizes these recommendations, which must now be
implemented in all EU member states.

As a result of an earlier pediatric clinical development program, Lipitor
has been approved for use in children (aged 10 to 17 years) with heterozygous
familial hypercholesterolemia in the United States since 2002.

Important U.S. Prescribing Information

LIPITOR is a prescription medicine that is used along with a low-fat
diet, and when diet and exercise are not enough. It lowers the LDL ("bad"
cholesterol) and triglycerides in your blood. It can raise your HDL ("good"
cholesterol) as well. LIPITOR can lower the risk for heart attack, stroke,
certain types of heart surgery, and chest pain in patients who have heart
disease or risk factors for heart disease such as age, smoking, high blood
pressure, low HDL, or family history of early heart disease.

LIPITOR can lower the risk for heart attack or stroke in patients with
diabetes and risk factors such as diabetic eye or kidney problems, smoking,
or high blood pressure.

LIPITOR is not for everyone. It is not for those with liver problems. And
it is not for women who are nursing, pregnant or may become pregnant.

Patients taking LIPITOR should tell their doctor if they feel any new
muscle pain or weakness. This could be a sign of rare but serious muscle side
effects. Patients should tell their doctor about all medications they take.
This may help avoid serious drug interactions. Doctors should do blood tests
to check your liver function before and during treatment and may adjust the
dose. Common side effects are diarrhea, upset stomach, muscle and joint pain,
and changes in some blood tests.

For additional product information, visit

Pfizer Inc: Working Together for a Healthier World(TM)

At Pfizer, we apply science and our global resources to improve health
and well-being at every stage of life. We strive to set the standard for
quality, safety and value in the discovery, development and manufacturing of
medicines for people and animals. Our diversified global health care
portfolio includes human and animal biologic and small molecule medicines and
vaccines, as well as nutritional products and many of the world's best-known
consumer products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and cures that
challenge the most feared diseases of our time. Consistent with our
responsibility as the world's leading biopharmaceutical company, we also
collaborate with health care providers, governments and local communities to
support and expand access to reliable, affordable health care around the
world. For more than 150 years, Pfizer has worked to make a difference for
all who rely on us. To learn more about our commitments, please visit us at


The information contained in this release is as of July 6, 2010. Pfizer
assumes no obligation to update forward-looking statements contained in this
release as the result of new information or future events or developments.

This release contains forward-looking information that involves
substantial risks and uncertainties. These include, among other things, the
Company's ability to satisfy the procedural requirements of the EU Paediatric
Medicines Regulation relating to the application for the additional six
months of patent/SPC protection in certain EU countries.

A further list and description of risks and uncertainties can be found in
Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31,
and in its reports on Form 10-Q and Form 8-K.

1. Regulation (EC) No 1901/2006 of the European Parliament and of the
Council on medicinal products for paediatric use, amended by Regulation (EC)
No 1902/2006.

Media: Andrew Thomas, +44-1737-330611, MacKay Jimeson, +1-212-733-2324; or Investor Contact: Suzanne Harnett, +1-212-733-8009

will not be displayed